Insider

Moderna, Inc.

MRNA Health Care · 4 analyses · 1 expectation tracked

Moderna reported $1.3B in revenue (+29.2% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 1 open management expectation for this company. 3 insider sales recorded.

Mentioned in recent filings: Ukraine Tariffs Going-concern doubt

What changed

What changed

Moderna updates credit terms and reports officer stock sale

On November 9, 2026, Moderna, Inc. amended its credit agreement, lowering interest rates and extending debt maturities. Separately, on November 16, 2026, officer Stephen Hoge filed a notice of a proposed sale of 39,160 shares under a trading plan. These steps reflect the company's financial planning and planned executive activity.

· Moderna, Inc.
What changed

Moderna Announces Chief Legal Officer Departure

Moderna, Inc. entered into a retirement agreement with its chief legal officer, Shannon Thyme Klinger, whose employment will end on March 31, 2027. Under the agreement, the company will pay her $1,628,300 in severance over 12 months following her departure.

· Moderna, Inc.
What changed

Moderna appoints Juan Andres as chief operating officer and expands its vaccine portfolio

Moderna announced the appointment of Juan Andres as chief operating officer, effective Oct. 5, 2026, with a base salary of $800,000, a cash bonus target of up to 90% of salary and a new equity grant worth $5,000,000. At the same time, the company said Jerh Collins, chief technical operations and quality officer, will retire, and that its infectious disease franchise now includes five approved vaccines, adding a seasonal flu shot approved by the U.S. FDA and a flu‑COVID combination vaccine cleared by the European Commission.

· Moderna, Inc.

Company history

October 2026

Moderna, Inc.: 12 recorded developments from 2 official sources in 2026-10.

  • 2026-09-16: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-14 to 2026-09-15, 80,575 disposed, total value 11,691,419.89 USD at a weighted average price of 145.0998 USD; owned after the last one: 1,562,029 Source
  • 2026-09-30: The target value for this annual equity award will be $4,000,000 to $5,000,000, subject to adjustment by the Compensation Committee. Source
  • 2026-09-30: Mr. Andres will be eligible for all compensation and benefit plans available to the Company's executive officers, as described in the Proxy Statement. Source
  • 2026-09-30: Mr. Andres will participate in the Company's Amended and Restated Executive Severance Plan and has entered into an indemnification agreement with the Company, consistent with the form of the existing indemnification agreement entered into between the Company and its executive officers. Source
  • 2026-09-30: Mr. Andres has also entered into an employee confidentiality, assignment, nonsolicitation and noncompetition agreement. Source
  • 2026-09-30: The Company further announced that Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer will retire from the Company. Source
  • 2026-09-30: On September 30, 2026, the Company issued a press release announcing the appointment of Mr. Andres as COO. Source
  • 2026-09-30: Moderna announced the appointment of Juan Andres as its Chief Operating Officer (COO) effective October 5, 2026. Source
  • 2026-09-30: In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephane Bancel and serve on the Company's Executive Committee. Source
  • 2026-09-30: In connection with his employment with the Company as COO, Mr. Andres will receive an initial annual base salary of $800,000. Source
  • 2026-09-30: Mr. Andres will also be eligible for an annual cash bonus with an annual incentive target of 90% of his annual base salary, based upon achievement of certain individual and/or company performance goals. Source
  • 2026-09-30: Mr. Andres will also be eligible to receive a new hire equity award equivalent to a total value of $5,000,000, subject to a four-year vesting period. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 6, 2026. SEC

LatestEarlierChange
Revenue quarter$1.3B$1B+29.2%
Operating income quarter$130M−$260M+150.0%
Net income quarter$162M−$200M+181.0%
Diluted EPS quarter$0.38−$0.51+174.5%
Operating cash flow year to date−$2.7B−$2.8B+3.1%
Cash and cash equivalents balance$1.2B$2.6B-53.9%

Next results expected around February 5, 2027 (estimate: the quarter ending about December 30, 2026 plus the 37 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Moderna, Inc. MRNA$1.3B+29.2%9.9%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Shannon Thyme Klinger will continue employment with Moderna, Inc. until March 31, 2027, and transition her duties as requested by the company.

    Said November 13, 2026 · Period named: March 31, 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 13, 2026Director or officer departure or appointment (8-K item 5.02)8-K
September 30, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 17, 2026Hoge StephenPlanned sale 10b5-1 plan39,215—$8,298,105SEC
November 16, 2026Hoge StephenPlanned sale 10b5-1 plan39,160—$8,601,863SEC
October 15, 2026Stephen HogeSale 10b5-1 plan78,369$217.10$17,013,538SEC
October 15, 2026Hoge StephenPlanned sale 10b5-1 plan39,145—$8,640,033SEC
October 14, 2026Hoge StephenPlanned sale 10b5-1 plan39,224—$8,373,519SEC
September 15, 2026Stephen HogeSale 10b5-1 plan80,575$145.10$11,691,420SEC
September 15, 2026Hoge StephenPlanned sale 10b5-1 plan40,281—$5,883,709SEC
September 14, 2026Hoge StephenPlanned sale 10b5-1 plan40,294—$5,807,746SEC
September 10, 2026James M MockSale 10b5-1 plan34,836$134.49$4,685,094SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
Fidelity (FMR)58,955,948$11,353,146,936+13.7%Q3 2026
BlackRock27,797,163$5,352,899,587-9.2%Q3 2026
State Street15,471,910$2,979,425,709-1.6%Q3 2026
Geode Capital Management10,244,440$1,969,298,480+5.5%Q3 2026
Millennium Management3,893,867$749,841,968+787.8%Q3 2026
Wellington Management3,715,578$715,508,855+50.9%Q3 2026
Norges Bank (Norway's sovereign fund)3,026,074$211,915,962—Q2 2026
Two Sigma Investments469,538$90,418,933-93.5%Q3 2026
Renaissance Technologies881,200$44,764,960—Q1 2026
Citadel Advisors116,160$22,368,931-60.6%Q3 2026
Bridgewater Associates72,342$13,930,899+527.6%Q3 2026
D. E. Shaw & Co.26,170$5,039,557+4.9%Q3 2026
T. Rowe Price7,616,737$1,466,756+36.3%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.